<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="London, England pmcid: 7476354 doi: 10.1177/1759720X2094729610.1177_1759720X20947296 : When Rheumatology and" exact="Infectious" post="Disease Come Together: Review Oral disease-modifying antirheumatic drugs and"/>
 <result pre="England pmcid: 7476354 doi: 10.1177/1759720X2094729610.1177_1759720X20947296 : When Rheumatology and Infectious" exact="Disease" post="Come Together: Review Oral disease-modifying antirheumatic drugs and immunosuppressants"/>
 <result pre="Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). Abstract There have been several episodes of" exact="viral infection" post="evolving into epidemics in recent decades, and severe acute"/>
 <result pre="page (https://us.sagepub.com/en-us/nam/open-access-at-sage). Abstract There have been several episodes of viral" exact="infection" post="evolving into epidemics in recent decades, and severe acute"/>
 <result pre="viral infection evolving into epidemics in recent decades, and severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) is the latest example."/>
 <result pre="infection evolving into epidemics in recent decades, and severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) is the latest example. Its"/>
 <result pre="evolving into epidemics in recent decades, and severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) is the latest example. Its high"/>
 <result pre="the category of immunosuppressive drugs usually poses a risk of" exact="infection" post="due to interference of the immune system, some of"/>
 <result pre="review article. Lay summary Immunosuppressants often raise the concern of" exact="infection" post="risks, especially for patients with underlying immune disorders. However,"/>
 <result pre="the concern of infection risks, especially for patients with underlying" exact="immune disorders." post="However, some disease-modifying antirheumatic drugs (DMARDs) with inherent antiviral"/>
 <result pre="would be a reasonable choice in the situation of concomitant" exact="viral" post="infections and flare up of autoimmune diseases. This review"/>
 <result pre="be a reasonable choice in the situation of concomitant viral" exact="infections" post="and flare up of autoimmune diseases. This review covers"/>
 <result pre="the situation of concomitant viral infections and flare up of" exact="autoimmune diseases." post="This review covers DMARDs of treatment potential for SARS-CoV-2"/>
 <result pre="in part II. baricitinib COVID-19 hydroxychloroquine immunosuppressant thalidomide virus Introduction" exact="Infections" post="are a common concern of immunosuppressive drugs. However, some"/>
 <result pre="safely used or even beneficial in patients with selected concomitant" exact="viral" post="infections. Certain DMARDs may even be considered as an"/>
 <result pre="(b) blockage of receptors, (c) inhibition of necessary molecules for" exact="viral" post="replication in the hosts, or (d) amelioration of inflammatory"/>
 <result pre="decrease the susceptibility or enhance host ability to defend against" exact="viral infection." post="The following review focuses on the immunosuppressants/DMARDs which have"/>
 <result pre="of the imperative demand to control the recently discovered severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), DMARDs with treatment potential"/>
 <result pre="the imperative demand to control the recently discovered severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), DMARDs with treatment potential are"/>
 <result pre="imperative demand to control the recently discovered severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), DMARDs with treatment potential are covered"/>
 <result pre="additional studies of interest. Figure 1. Article selection flowchart. AIDS," exact="acquired immunodeficiency syndrome;" post="COVID-19, coronavirus disease 2019; HBV, hepatitis B virus; HCV,"/>
 <result pre="studies of interest. Figure 1. Article selection flowchart. AIDS, acquired" exact="immunodeficiency" post="syndrome; COVID-19, coronavirus disease 2019; HBV, hepatitis B virus;"/>
 <result pre="1. Article selection flowchart. AIDS, acquired immunodeficiency syndrome; COVID-19, coronavirus" exact="disease" post="2019; HBV, hepatitis B virus; HCV, hepatitis C virus;"/>
 <result pre="flowchart. AIDS, acquired immunodeficiency syndrome; COVID-19, coronavirus disease 2019; HBV," exact="hepatitis" post="B virus; HCV, hepatitis C virus; HIV, human immunodeficiency"/>
 <result pre="syndrome; COVID-19, coronavirus disease 2019; HBV, hepatitis B virus; HCV," exact="hepatitis C" post="virus; HIV, human immunodeficiency virus; HSV, herpes simplex virus;"/>
 <result pre="HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human" exact="immunodeficiency" post="virus; HSV, herpes simplex virus; RCT, randomized controlled trial;"/>
 <result pre="virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HSV," exact="herpes" post="simplex virus; RCT, randomized controlled trial; SARS-CoV-2, severe acute"/>
 <result pre="HSV, herpes simplex virus; RCT, randomized controlled trial; SARS-CoV-2, severe" exact="acute" post="respiratory syndrome coronavirus 2. Part I: DMARDs for severe"/>
 <result pre="herpes simplex virus; RCT, randomized controlled trial; SARS-CoV-2, severe acute" exact="respiratory" post="syndrome coronavirus 2. Part I: DMARDs for severe acute"/>
 <result pre="simplex virus; RCT, randomized controlled trial; SARS-CoV-2, severe acute respiratory" exact="syndrome" post="coronavirus 2. Part I: DMARDs for severe acute respiratory"/>
 <result pre="acute respiratory syndrome coronavirus 2. Part I: DMARDs for severe" exact="acute" post="respiratory syndrome coronavirus 2 Coronavirus disease 2019 (COVID-19) is"/>
 <result pre="respiratory syndrome coronavirus 2. Part I: DMARDs for severe acute" exact="respiratory" post="syndrome coronavirus 2 Coronavirus disease 2019 (COVID-19) is a"/>
 <result pre="syndrome coronavirus 2. Part I: DMARDs for severe acute respiratory" exact="syndrome" post="coronavirus 2 Coronavirus disease 2019 (COVID-19) is a newly"/>
 <result pre="I: DMARDs for severe acute respiratory syndrome coronavirus 2 Coronavirus" exact="disease" post="2019 (COVID-19) is a newly emerged lethal pandemic caused"/>
 <result pre="between humans. While most patients experience mild symptoms, some develop" exact="acute" post="respiratory distress syndrome, multi-organ failure, or even death. As"/>
 <result pre="humans. While most patients experience mild symptoms, some develop acute" exact="respiratory" post="distress syndrome, multi-organ failure, or even death. As of"/>
 <result pre="more than 4.90 million cases have been reported, causing a" exact="total" post="of 0.32 million deaths. SARS-CoV-2 is a single-strand ribonucleic"/>
 <result pre="and prevent malaria. They are also used as DMARDs for" exact="rheumatoid arthritis," post="lupus erythematosus, and porphyria cutanea tarda. In addition, the"/>
 <result pre="malaria. They are also used as DMARDs for rheumatoid arthritis," exact="lupus erythematosus," post="and porphyria cutanea tarda. In addition, the application for"/>
 <result pre="also used as DMARDs for rheumatoid arthritis, lupus erythematosus, and" exact="porphyria" post="cutanea tarda. In addition, the application for viral infections"/>
 <result pre="erythematosus, and porphyria cutanea tarda. In addition, the application for" exact="viral" post="infections in off-label use has recently been investigated vigorously."/>
 <result pre="and porphyria cutanea tarda. In addition, the application for viral" exact="infections" post="in off-label use has recently been investigated vigorously. The"/>
 <result pre="COVID-19.5 A preliminary study conducted in China showed benefits in" exact="pneumonia" post="image, shortening of disease course, and promoting a virus-negative"/>
 <result pre="conducted in China showed benefits in pneumonia image, shortening of" exact="disease" post="course, and promoting a virus-negative conversion compared with control"/>
 <result pre="vitro, and the possibility of preventing from progressing to severe" exact="respiratory" post="tract infections, two French trials which combined the use"/>
 <result pre="or HCQ in the treatment of COVID-19 pneumonia. In the" exact="absence of" post="other confirmed effective therapy specific to SARS-CoV-2, both drugs"/>
 <result pre="RCT, randomized-controlled trial; RT-PCR, real-time polymerase chain reaction; SARS-CoV-2, severe" exact="acute" post="respiratory syndrome coronavirus 2; TNF, tumor necrosis factor. Baricitinib"/>
 <result pre="randomized-controlled trial; RT-PCR, real-time polymerase chain reaction; SARS-CoV-2, severe acute" exact="respiratory" post="syndrome coronavirus 2; TNF, tumor necrosis factor. Baricitinib Baricitinib,"/>
 <result pre="trial; RT-PCR, real-time polymerase chain reaction; SARS-CoV-2, severe acute respiratory" exact="syndrome" post="coronavirus 2; TNF, tumor necrosis factor. Baricitinib Baricitinib, blocking"/>
 <result pre="chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TNF," exact="tumor" post="necrosis factor. Baricitinib Baricitinib, blocking Janus kinase (JAK)1 and"/>
 <result pre="Baricitinib, blocking Janus kinase (JAK)1 and JAK2, is approved for" exact="rheumatoid arthritis" post="and has been investigated in atopic dermatitis. SARS-CoV-2 binds"/>
 <result pre="blocking Janus kinase (JAK)1 and JAK2, is approved for rheumatoid" exact="arthritis" post="and has been investigated in atopic dermatitis. SARS-CoV-2 binds"/>
 <result pre="is approved for rheumatoid arthritis and has been investigated in" exact="atopic dermatitis." post="SARS-CoV-2 binds on the angiotensin-converting enzyme 2 (ACE2) receptors"/>
 <result pre="four Italian patients with moderate-to-severe unstable COVID-19 infections. Except one" exact="female" post="nurse, the other three male individuals were aged 51â€&quot;76"/>
 <result pre="with high body mass index, and two of them had" exact="chronic" post="obstructive pulmonary disease plus hypertension histories. Under baricitinib 2â€‰mg"/>
 <result pre="body mass index, and two of them had chronic obstructive" exact="pulmonary" post="disease plus hypertension histories. Under baricitinib 2â€‰mg or 4â€‰mg"/>
 <result pre="mass index, and two of them had chronic obstructive pulmonary" exact="disease" post="plus hypertension histories. Under baricitinib 2â€‰mg or 4â€‰mg for"/>
 <result pre="and two of them had chronic obstructive pulmonary disease plus" exact="hypertension" post="histories. Under baricitinib 2â€‰mg or 4â€‰mg for 10â€&quot;12â€‰days, all"/>
 <result pre="data [interleukin-6 (IL-6), C-reactive protein, ferritin, liver enzymes, D-dimer, and" exact="viral" post="loads].13 In one controlled open-label study (nâ€‰=â€‰24), patients were"/>
 <result pre="a cytokine storm syndrome, which features hypercytokinemia and multi-organ failure." exact="Elevated" post="ferritin and IL-6 in COVID-19 cases were predictive of"/>
 <result pre="interference of JAK inhibitors with IFN-mediated antiviral activities. IFNs prohibit" exact="viral" post="spreading in the early phase of infections. In animal"/>
 <result pre="of infections. In animal models of SARS and Middle East" exact="respiratory" post="syndrome (MERS), IFN-Î± and IFN-Î² showed benefit at the"/>
 <result pre="infections. In animal models of SARS and Middle East respiratory" exact="syndrome" post="(MERS), IFN-Î± and IFN-Î² showed benefit at the early"/>
 <result pre="evaluate the optimal timing, duration, and safety of baricitinib in" exact="viral" post="infections, including SARS-CoV-2.19â€&quot;21 Cyclosporine A Cyclosporine A (CsA) is"/>
 <result pre="including SARS-CoV-2.19â€&quot;21 Cyclosporine A Cyclosporine A (CsA) is indicated for" exact="rheumatoid arthritis," post="psoriasis, organ transplants to prevent injection, and keratoconjunctivitis sicca."/>
 <result pre="for rheumatoid arthritis, psoriasis, organ transplants to prevent injection, and" exact="keratoconjunctivitis" post="sicca. It is also used in severe atopic dermatitis,"/>
 <result pre="injection, and keratoconjunctivitis sicca. It is also used in severe" exact="atopic dermatitis," post="chronic urticaria, pyoderma gangrenosum Kimura disease, acute systemic mastocytosis,"/>
 <result pre="keratoconjunctivitis sicca. It is also used in severe atopic dermatitis," exact="chronic" post="urticaria, pyoderma gangrenosum Kimura disease, acute systemic mastocytosis, and"/>
 <result pre="It is also used in severe atopic dermatitis, chronic urticaria," exact="pyoderma gangrenosum" post="Kimura disease, acute systemic mastocytosis, and ulcerative colitis. CsA"/>
 <result pre="also used in severe atopic dermatitis, chronic urticaria, pyoderma gangrenosum" exact="Kimura disease," post="acute systemic mastocytosis, and ulcerative colitis. CsA inhibits lymphocyte"/>
 <result pre="in severe atopic dermatitis, chronic urticaria, pyoderma gangrenosum Kimura disease," exact="acute" post="systemic mastocytosis, and ulcerative colitis. CsA inhibits lymphocyte function,"/>
 <result pre="severe atopic dermatitis, chronic urticaria, pyoderma gangrenosum Kimura disease, acute" exact="systemic" post="mastocytosis, and ulcerative colitis. CsA inhibits lymphocyte function, mainly"/>
 <result pre="chronic urticaria, pyoderma gangrenosum Kimura disease, acute systemic mastocytosis, and" exact="ulcerative colitis." post="CsA inhibits lymphocyte function, mainly T cells, by forming"/>
 <result pre="promote the production of IFNs and cytokines to defend against" exact="viral" post="infections. Thus, mitochondria appear to play a vital role"/>
 <result pre="receptor of SARS-CoV-2, is also the target antigen of clinically" exact="amyopathic dermatomyositis" post="(CADM). Patients with MDA5 plus CADM have higher risks"/>
 <result pre="of SARS-CoV-2, is also the target antigen of clinically amyopathic" exact="dermatomyositis" post="(CADM). Patients with MDA5 plus CADM have higher risks"/>
 <result pre="plus CADM have higher risks of developing rapidly progressive interstitial" exact="lung diseases" post="and respiratory failure, while this could be reversed by"/>
 <result pre="higher risks of developing rapidly progressive interstitial lung diseases and" exact="respiratory" post="failure, while this could be reversed by calcineurin inhibitors."/>
 <result pre="functions, CsA was proposed as a modulator for cytokine storm" exact="syndrome" post="in COVID-19 infections.25 Mycophenolate mofetil and mycophenolic acid Mycophenolic"/>
 <result pre="steroid-sparing agents for conditions such as pemphigus, BehÃ§etâ€™s disease, and" exact="lupus erythematosus." post="Although they were associated with higher risk of opportunistic"/>
 <result pre="lupus erythematosus. Although they were associated with higher risk of" exact="opportunistic infections" post="including herpes zoster, cytomegalovirus (CMV), and BK virus (BKV)"/>
 <result pre="erythematosus. Although they were associated with higher risk of opportunistic" exact="infections" post="including herpes zoster, cytomegalovirus (CMV), and BK virus (BKV)"/>
 <result pre="they were associated with higher risk of opportunistic infections including" exact="herpes zoster," post="cytomegalovirus (CMV), and BK virus (BKV) nephropathy, literature also"/>
 <result pre="another essential enzyme for pyrimidine synthesis, and MMF might control" exact="viral infection" post="by depleting the intracellular pyrimidine pools.28 Thalidomide Thalidomide, a"/>
 <result pre="essential enzyme for pyrimidine synthesis, and MMF might control viral" exact="infection" post="by depleting the intracellular pyrimidine pools.28 Thalidomide Thalidomide, a"/>
 <result pre="Thalidomide Thalidomide, a derivative of glutamic acid, is approved for" exact="erythema nodosum" post="leprosum and is also used in many conditions such"/>
 <result pre="leprosum and is also used in many conditions such as" exact="prurigo" post="nodularis, pyoderma gangrenosum, Bechetâ€™s disease, lupus erythematosus and erythema"/>
 <result pre="is also used in many conditions such as prurigo nodularis," exact="pyoderma gangrenosum," post="Bechetâ€™s disease, lupus erythematosus and erythema multiforme. It exerts"/>
 <result pre="many conditions such as prurigo nodularis, pyoderma gangrenosum, Bechetâ€™s disease," exact="lupus erythematosus" post="and erythema multiforme. It exerts anti-inflammatory effect through cereblon"/>
 <result pre="as prurigo nodularis, pyoderma gangrenosum, Bechetâ€™s disease, lupus erythematosus and" exact="erythema multiforme." post="It exerts anti-inflammatory effect through cereblon E3 ubiquitin ligase"/>
 <result pre="exerts anti-inflammatory effect through cereblon E3 ubiquitin ligase as the" exact="primary" post="target and thus inhibits chemotaxis of leukocytes, monocytes as"/>
 <result pre="chemotaxis of leukocytes, monocytes as well as the production of" exact="tumor" post="necrosis factor (TNF)-alpha, IL-8, and IL-12. Case report: A"/>
 <result pre="which further suppresses the production of pro-inflammatory cytokines such as" exact="tumor" post="necrosis factor alpha (TNF-Î±) and IL-8, and prevents the"/>
 <result pre="patients with coexisting immune-based diseases and infections. Especially when the" exact="infection" post="is still in progression, choosing DMARDs with anti-microbial evidence"/>
 <result pre="DMARDs with anti-microbial evidence would bring double benefits for better" exact="infection" post="control without sacrificing underlying disease management. The antimicrobial mechanisms"/>
 <result pre="bring double benefits for better infection control without sacrificing underlying" exact="disease" post="management. The antimicrobial mechanisms of DMARDs are often distinct"/>
 <result pre="from their immunomodulatory pathway, and the efficacy is different in" exact="viral" post="species (Tables 2, 3 and 4). Table 2. Suggestions"/>
 <result pre="2. Suggestions for selecting DMARDs/immunosuppressants when immune-based diseases concomitant with" exact="viral infection." post="DrugsVirus Chloroquine/HCQ Baricitinib CsA Hydroxyurea Minocycline MMF/MPA Leflunomide Tofacitinib"/>
 <result pre="DNA, deoxyribonucleic acid; GAK, cyclin G-associated kinase; HCQ, hydroxychloroquine; HBV," exact="hepatitis" post="B virus; HCV, hepatitis C virus; HHV-8, human herpesvirus"/>
 <result pre="cyclin G-associated kinase; HCQ, hydroxychloroquine; HBV, hepatitis B virus; HCV," exact="hepatitis C" post="virus; HHV-8, human herpesvirus 8; HIV, human immunodeficiency virus;"/>
 <result pre="HCV, hepatitis C virus; HHV-8, human herpesvirus 8; HIV, human" exact="immunodeficiency" post="virus; HSV, herpes simplex virus; HTLV-1, human T-cellâ€&quot;lymphotrophic virus-1;"/>
 <result pre="virus; HHV-8, human herpesvirus 8; HIV, human immunodeficiency virus; HSV," exact="herpes" post="simplex virus; HTLV-1, human T-cellâ€&quot;lymphotrophic virus-1; IMPDH, inosine monophosphate"/>
 <result pre="virus; HTLV-1, human T-cellâ€&quot;lymphotrophic virus-1; IMPDH, inosine monophosphate dehydrogenase; JEV," exact="Japanese encephalitis" post="virus; MDA5, melanoma differentiation activated protein 5; MMF/MPA, mycophenolate"/>
 <result pre="HTLV-1, human T-cellâ€&quot;lymphotrophic virus-1; IMPDH, inosine monophosphate dehydrogenase; JEV, Japanese" exact="encephalitis" post="virus; MDA5, melanoma differentiation activated protein 5; MMF/MPA, mycophenolate"/>
 <result pre="virus-1; IMPDH, inosine monophosphate dehydrogenase; JEV, Japanese encephalitis virus; MDA5," exact="melanoma" post="differentiation activated protein 5; MMF/MPA, mycophenolate mofetil/mycophenolic acid; MPTP,"/>
 <result pre="transition pore opening; RCT, randomized-controlled trial; RNA, ribonucleic acid; RSV," exact="respiratory" post="syncytial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2."/>
 <result pre="trial; RNA, ribonucleic acid; RSV, respiratory syncytial virus; SARS-CoV-2, severe" exact="acute" post="respiratory syndrome coronavirus 2. Table 3. Mechanisms regarding antiviral"/>
 <result pre="RNA, ribonucleic acid; RSV, respiratory syncytial virus; SARS-CoV-2, severe acute" exact="respiratory" post="syndrome coronavirus 2. Table 3. Mechanisms regarding antiviral activities"/>
 <result pre="ribonucleic acid; RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory" exact="syndrome" post="coronavirus 2. Table 3. Mechanisms regarding antiviral activities of"/>
 <result pre="3. Mechanisms regarding antiviral activities of DMARDs and immunosuppressants. Medications" exact="Viral" post="susceptibility Proposed antiviral mechanisms ChloroquineHCQ SARS-CoV, HIV, dengue virus,"/>
 <result pre="Viral susceptibility Proposed antiviral mechanisms ChloroquineHCQ SARS-CoV, HIV, dengue virus," exact="chikungunya" post="virus, influenza A virus, HCV, Zika virus (1)â€ƒIncrease endosomal"/>
 <result pre="and trafficking Flavivirus (Zika virus, dengue virus, West Nile virus," exact="yellow fever" post="virus) Block the interaction between host cyclophilins and flaviviral"/>
 <result pre="assembly(3)â€ƒparticle budding Hydroxyurea HIV (1)â€ƒInhibit DNA synthesis, slowing production of" exact="viral" post="DNA(2)â€ƒDeplete dNTP pools, which increase competitive ability of NRTIs"/>
 <result pre="HBV Unknown, inhibit HBV replication HSV Inhibit HSV DNA replication" exact="Parvovirus" post="B19 Unknown Minocycline HIV (1)â€ƒHigh affinity to HIV integrase"/>
 <result pre="HIV integrase and interaction with HIV integrase suppress the virus(2)â€ƒDecrease" exact="viral" post="expression from CD4+ T cells Japanese encephalitis virus Inhibit"/>
 <result pre="integrase suppress the virus(2)â€ƒDecrease viral expression from CD4+ T cells" exact="Japanese encephalitis" post="virus Inhibit microglial activation and neuronal apoptosis Dengue virus"/>
 <result pre="suppress the virus(2)â€ƒDecrease viral expression from CD4+ T cells Japanese" exact="encephalitis" post="virus Inhibit microglial activation and neuronal apoptosis Dengue virus"/>
 <result pre="CD4+ T cells Japanese encephalitis virus Inhibit microglial activation and" exact="neuronal" post="apoptosis Dengue virus Reduce viral RNA synthesis, intracellular envelope"/>
 <result pre="cells Japanese encephalitis virus Inhibit microglial activation and neuronal apoptosis" exact="Dengue" post="virus Reduce viral RNA synthesis, intracellular envelope protein expression,"/>
 <result pre="virus Inhibit microglial activation and neuronal apoptosis Dengue virus Reduce" exact="viral" post="RNA synthesis, intracellular envelope protein expression, and the production"/>
 <result pre="RNA synthesis, intracellular envelope protein expression, and the production of" exact="infectious" post="virions RSV (1)â€ƒReduce RSV-mediated cytopathic effects(2)â€ƒPrevent RSV infection by"/>
 <result pre="production of infectious virions RSV (1)â€ƒReduce RSV-mediated cytopathic effects(2)â€ƒPrevent RSV" exact="infection" post="by affecting RSV F protein production or maturation Enterovirus"/>
 <result pre="protein production or maturation Enterovirus 71 Reduce cytopathic effects and" exact="viral" post="protein expressions Influenza virus Reverse H7N9 replication West Nile"/>
 <result pre="H7N9 replication West Nile virus Anti-apoptotic properties result in neuroprotection." exact="Reovirus" post="Reduce apoptosis and antigen expression Rabies Reduce CD3+ cells"/>
 <result pre="Rabies Reduce CD3+ cells may impair the host to control" exact="disease" post="Mycophenolate mofetil/mycophenolic acid HIV Inhibit the dividing CD4+ T"/>
 <result pre="antiviral effect by depletion of this substrate Influenza virus Inhibit" exact="viral" post="mRNA and protein expression via inhibition of cellular IMPDH"/>
 <result pre="RSV Inhibit nucleocapsid tegumentation and thus prevents virion assembling Tofacitinib" exact="HTLV-1" post="HTLV-1-induced ATLL is associated with JAK3 mutations; tofacitinib inhibits"/>
 <result pre="to trigger antiviral response AAK1, AP2-associated protein kinase 1; ATLL," exact="adult" post="T-cell lymphoma/leukemia; BKV, BK virus; CMV, cytomegalovirus; DENV, dengue"/>
 <result pre="GAK, cyclin G-associated kinase; HAART, highly active antiretroviral therapy; HBV," exact="hepatitis" post="B virus; HCQ, hydroxychloroquine; HHV-8, human herpesvirus 8; HIV,"/>
 <result pre="B virus; HCQ, hydroxychloroquine; HHV-8, human herpesvirus 8; HIV, human" exact="immunodeficiency" post="virus; HTLV-I, human T-cell lymphotrophic virus-1; IMPDH, inosine monophosphate"/>
 <result pre="IMPDH, inosine monophosphate dehydrogenase; JAK, Janus kinase; MERS-CoV, Middle East" exact="respiratory" post="syndrome coronavirus; mRNA, messenger RNA; NRTI, nucleoside analog reverse-transcriptase"/>
 <result pre="inosine monophosphate dehydrogenase; JAK, Janus kinase; MERS-CoV, Middle East respiratory" exact="syndrome" post="coronavirus; mRNA, messenger RNA; NRTI, nucleoside analog reverse-transcriptase inhibitor;"/>
 <result pre="analog reverse-transcriptase inhibitor; RCT, randomized-controlled trial; RNA, ribonucleic acid; RSV," exact="respiratory" post="syncytial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2."/>
 <result pre="trial; RNA, ribonucleic acid; RSV, respiratory syncytial virus; SARS-CoV-2, severe" exact="acute" post="respiratory syndrome coronavirus 2. Table 4. Clinical studies regarding"/>
 <result pre="RNA, ribonucleic acid; RSV, respiratory syncytial virus; SARS-CoV-2, severe acute" exact="respiratory" post="syndrome coronavirus 2. Table 4. Clinical studies regarding antiviral"/>
 <result pre="ribonucleic acid; RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory" exact="syndrome" post="coronavirus 2. Table 4. Clinical studies regarding antiviral activities"/>
 <result pre="Clinical studies regarding antiviral activities of DMARDs and immunosuppressants. Medications" exact="Viral" post="susceptibility In vitro Animal study Clinical report ChloroquineHCQ SARS-CoV"/>
 <result pre="transmission36âœ&quot; RCT (nâ€‰=â€‰12): reduced T-cell immune activation; no effect on" exact="viral" post="load37âœ&quot; Prospective (nâ€‰=â€‰20): significant reduction immune activation38âœ— RCT (nâ€‰=â€‰83):"/>
 <result pre="activation38âœ— RCT (nâ€‰=â€‰83): no efficacy39âœ— Single-arm, pilot (nâ€‰=â€‰20): not beneficial40" exact="Dengue" post="virus âœ&quot; Farias et al.41 âœ&quot; Farias et al.42"/>
 <result pre="Placebo-controlled trial (nâ€‰=â€‰120): increased sustained virological response60 Flavivirus (Zika virus," exact="Dengue" post="virus, West Nile virus, Yellow fever virus) âœ&quot; Qing"/>
 <result pre="virological response60 Flavivirus (Zika virus, Dengue virus, West Nile virus," exact="Yellow fever" post="virus) âœ&quot; Qing et al.,61 Barrows et al.62 Betaretrovirus"/>
 <result pre="âœ&quot; Lori and Lisziewicz64 âœ&quot; RCT (nâ€‰=â€‰57): greater decrease in" exact="viral" post="load65âœ&quot; RCT (nâ€‰=â€‰144): greater decrease of HIV RNA levels66âœ&quot;"/>
 <result pre="serum HCV RNA levels71 HBV âœ&quot; nâ€‰=â€‰4: significant decrease of" exact="viral" post="loads in all patients72âœ— nâ€‰=â€‰1, HBV reactivation73 HSV âœ&quot;"/>
 <result pre="HBV reactivation73 HSV âœ&quot; Rosenkranz and Becker,74 Sergerie and Boivin75" exact="Parvovirus" post="B19 âœ&quot; Bonvicini et al.76 âœ&quot; Retrospective review (nâ€‰=â€‰120):"/>
 <result pre="in cognitive function80âœ— RCT (nâ€‰=â€‰73): no difference in cognitive function81" exact="Japanese encephalitis" post="virus âœ&quot; Mishra and Basu82 âœ&quot; Reduce viral titers,"/>
 <result pre="cognitive function80âœ— RCT (nâ€‰=â€‰73): no difference in cognitive function81 Japanese" exact="encephalitis" post="virus âœ&quot; Mishra and Basu82 âœ&quot; Reduce viral titers,"/>
 <result pre="function81 Japanese encephalitis virus âœ&quot; Mishra and Basu82 âœ&quot; Reduce" exact="viral" post="titers, neuronal apoptosis83 âœ&quot; RCT (nâ€‰=â€‰44), 1â€&quot;13 years: duration"/>
 <result pre="encephalitis virus âœ&quot; Mishra and Basu82 âœ&quot; Reduce viral titers," exact="neuronal" post="apoptosis83 âœ&quot; RCT (nâ€‰=â€‰44), 1â€&quot;13 years: duration of fever,"/>
 <result pre="mortality rate unchanged84âœ&quot; RCT (nâ€‰=â€‰281): a trend towards better outcomes85" exact="Dengue" post="virus âœ&quot; Leela et al.86 RSV âœ&quot; Bawage et"/>
 <result pre="âœ&quot; Liao et al.88 âœ&quot; Decrease mortality rates, clinical scores," exact="viral" post="titers68 Influenza virus âœ&quot; Josset et al.89 West Nile"/>
 <result pre="Josset et al.89 West Nile virus âœ&quot; Michaelis et al.90" exact="Reovirus" post="âœ&quot; Delay encephalitis onset; reduce mortality91 Rabies âœ— Worse,"/>
 <result pre="West Nile virus âœ&quot; Michaelis et al.90 Reovirus âœ&quot; Delay" exact="encephalitis" post="onset; reduce mortality91 Rabies âœ— Worse, higher mortality rate92"/>
 <result pre="T-cell populations.93 âœ&quot; RCT (nâ€‰=â€‰17): combine MMF and HAART delayed" exact="viral" post="load rebound and improved control of viral replication26 Influenza"/>
 <result pre="and HAART delayed viral load rebound and improved control of" exact="viral" post="replication26 Influenza virus âœ&quot; To et al.27 âœ&quot; All"/>
 <result pre="Influenza virus âœ&quot; To et al.27 âœ&quot; All mice survived;" exact="viral" post="titers in lungs markedly reduced94 MERS-CoV âœ&quot; Chan et"/>
 <result pre="in lungs markedly reduced94 MERS-CoV âœ&quot; Chan et al.95 âœ—" exact="Severe" post="and fatal disease; higher viral loads than the untreated"/>
 <result pre="âœ&quot; Chan et al.95 âœ— Severe and fatal disease; higher" exact="viral" post="loads than the untreated animals96 Leflunomide HSV âœ&quot; Knight"/>
 <result pre="âœ&quot; Hossain and Margolis,100 Schlapfer et al.101 âœ&quot; RCT (nâ€‰=â€‰18):" exact="stable" post="CD4+ T-cell counts102 Molluscum and verruca âœ&quot; nâ€‰=â€‰3 with"/>
 <result pre="al.101 âœ&quot; RCT (nâ€‰=â€‰18): stable CD4+ T-cell counts102 Molluscum and" exact="verruca" post="âœ&quot; nâ€‰=â€‰3 with AD103âœ&quot; nâ€‰=â€‰3 with renal transplantation104 CMV"/>
 <result pre="improvement of renal function108 RSV âœ&quot; Dunn et al.109 âœ&quot;" exact="Viral" post="loads reduced109 Tofacitinib HTLV-1 âœ&quot; Prolong survival duration110 Thalidomide"/>
 <result pre="RSV âœ&quot; Dunn et al.109 âœ&quot; Viral loads reduced109 Tofacitinib" exact="HTLV-1" post="âœ&quot; Prolong survival duration110 Thalidomide HHV-8 âœ&quot; Phase II"/>
 <result pre="Prolong survival duration110 Thalidomide HHV-8 âœ&quot; Phase II (nâ€‰=â€‰17): 35%" exact="partial" post="response rate111âœ&quot; Phase II (nâ€‰=â€‰20): 40% partial responses and"/>
 <result pre="II (nâ€‰=â€‰17): 35% partial response rate111âœ&quot; Phase II (nâ€‰=â€‰20): 40%" exact="partial" post="responses and 10% stable disease112 AD, atopic dermatitis; CMV,"/>
 <result pre="response rate111âœ&quot; Phase II (nâ€‰=â€‰20): 40% partial responses and 10%" exact="stable" post="disease112 AD, atopic dermatitis; CMV, cytomegalovirus; CsA, cyclosporine A;"/>
 <result pre="II (nâ€‰=â€‰20): 40% partial responses and 10% stable disease112 AD," exact="atopic dermatitis;" post="CMV, cytomegalovirus; CsA, cyclosporine A; DENV, dengue virus; DMARDs,"/>
 <result pre="anti-rheumatic drugs; HAART, highly active antiretroviral therapy; Hb, hemoglobin; HBV," exact="hepatitis" post="B virus; HCQ, hydroxychloroquine; HCV, hepatitis C virus; HHV-8,"/>
 <result pre="therapy; Hb, hemoglobin; HBV, hepatitis B virus; HCQ, hydroxychloroquine; HCV," exact="hepatitis C" post="virus; HHV-8, human herpesvirus 8; HIV, human immunodeficiency virus;"/>
 <result pre="HCV, hepatitis C virus; HHV-8, human herpesvirus 8; HIV, human" exact="immunodeficiency" post="virus; HSV, herpes simplex virus; HTLV-I, human T cell"/>
 <result pre="virus; HHV-8, human herpesvirus 8; HIV, human immunodeficiency virus; HSV," exact="herpes" post="simplex virus; HTLV-I, human T cell lymphotrophic virus-1; MERS-CoV,"/>
 <result pre="virus; HTLV-I, human T cell lymphotrophic virus-1; MERS-CoV, Middle East" exact="respiratory" post="syndrome coronavirus; MMF, mycophenolate mofetil; PCT, porphyria cutanea tarda;"/>
 <result pre="HTLV-I, human T cell lymphotrophic virus-1; MERS-CoV, Middle East respiratory" exact="syndrome" post="coronavirus; MMF, mycophenolate mofetil; PCT, porphyria cutanea tarda; RCT,"/>
 <result pre="MERS-CoV, Middle East respiratory syndrome coronavirus; MMF, mycophenolate mofetil; PCT," exact="porphyria" post="cutanea tarda; RCT, randomized-controlled trial; RSV, respiratory syncytial virus;"/>
 <result pre="mycophenolate mofetil; PCT, porphyria cutanea tarda; RCT, randomized-controlled trial; RSV," exact="respiratory" post="syncytial virus; RNA, ribonucleic acid; SARS-CoV, severe acute respiratory"/>
 <result pre="trial; RSV, respiratory syncytial virus; RNA, ribonucleic acid; SARS-CoV, severe" exact="acute" post="respiratory syndrome coronavirus. Leflunomide Leflunomide is approved for rheumatoid"/>
 <result pre="RSV, respiratory syncytial virus; RNA, ribonucleic acid; SARS-CoV, severe acute" exact="respiratory" post="syndrome coronavirus. Leflunomide Leflunomide is approved for rheumatoid arthritis"/>
 <result pre="respiratory syncytial virus; RNA, ribonucleic acid; SARS-CoV, severe acute respiratory" exact="syndrome" post="coronavirus. Leflunomide Leflunomide is approved for rheumatoid arthritis and"/>
 <result pre="severe acute respiratory syndrome coronavirus. Leflunomide Leflunomide is approved for" exact="rheumatoid arthritis" post="and psoriatic arthritis (not in the United States). Leflunomide"/>
 <result pre="acute respiratory syndrome coronavirus. Leflunomide Leflunomide is approved for rheumatoid" exact="arthritis" post="and psoriatic arthritis (not in the United States). Leflunomide"/>
 <result pre="syndrome coronavirus. Leflunomide Leflunomide is approved for rheumatoid arthritis and" exact="psoriatic arthritis" post="(not in the United States). Leflunomide inhibits the synthesis"/>
 <result pre="coronavirus. Leflunomide Leflunomide is approved for rheumatoid arthritis and psoriatic" exact="arthritis" post="(not in the United States). Leflunomide inhibits the synthesis"/>
 <result pre="improved with valacyclovir, foscarnet, and imiquimod. After 9â€‰months of leflunomide," exact="complete" post="regression of the lesions was noted. Leflunomide has both"/>
 <result pre="formation is an immune reconstruction phenomenon in HIV patients.99 Human" exact="immunodeficiency" post="virus An RCT (nâ€‰=â€‰18) demonstrated leflunomide decreased the activation"/>
 <result pre="and CXCR4 was also reduced compared with placebo.102 Molluscum and" exact="verruca" post="Three patients with atopic dermatitis treated with azathioprine developed"/>
 <result pre="reduced compared with placebo.102 Molluscum and verruca Three patients with" exact="atopic dermatitis" post="treated with azathioprine developed multiple verrucae and molluscum contagiosum."/>
 <result pre="compared with placebo.102 Molluscum and verruca Three patients with atopic" exact="dermatitis" post="treated with azathioprine developed multiple verrucae and molluscum contagiosum."/>
 <result pre="with atopic dermatitis treated with azathioprine developed multiple verrucae and" exact="molluscum contagiosum." post="Due to treatment resistance, azathioprine was switched to leflunomide"/>
 <result pre="lesions subsided in three patients within 2â€‰months of leflunomide treatment.103" exact="Multiple" post="recalcitrant verrucae in three and molluscum in one of"/>
 <result pre="can serve as a potential option for patients with skin" exact="warts" post="or molluscum concomitant with immune conditions that require immunosuppressants."/>
 <result pre="Cytomegalovirus A review article collected 45 transplant recipients with CMV" exact="infection" post="treated by leflunomide. Among them, the plasma CMV viral"/>
 <result pre="CMV infection treated by leflunomide. Among them, the plasma CMV" exact="viral" post="load became undetectable in 33 patients (73%). Most of"/>
 <result pre="properties of leflunomide were not through blocking the replication of" exact="viral" post="DNA, so it is effective even in patients with"/>
 <result pre="system and lives there persistently. A sudden increase of BK-virus-associated" exact="nephropathy" post="is related to the administration of potent immunosuppressants such"/>
 <result pre="metabolites, but no significant improvement of renal function was noted.108" exact="Respiratory" post="syncytial virus (RSV) Treatment options for RSV are limited"/>
 <result pre="noted.108 Respiratory syncytial virus (RSV) Treatment options for RSV are" exact="limited" post="to supportive care or ribavirin with only marginal effectiveness."/>
 <result pre="showed a potent, dose-dependent anti-RSV activity in cell cultures.92 Also," exact="pulmonary" post="viral loads were prominently reduced in cotton rats, even"/>
 <result pre="a potent, dose-dependent anti-RSV activity in cell cultures.92 Also, pulmonary" exact="viral" post="loads were prominently reduced in cotton rats, even if"/>
 <result pre="if there was a 3-day delay of leflunomide administration after" exact="viral" post="inoculation.109 Leflunomide offers a dual benefit of both viral-load"/>
 <result pre="Tofacitinib Tofacitinib, a JAK1 and JAK3 inhibitor, is indicated in" exact="rheumatoid arthritis," post="ulcerative colitis, and psoriatic arthritis. It is also used"/>
 <result pre="a JAK1 and JAK3 inhibitor, is indicated in rheumatoid arthritis," exact="ulcerative colitis," post="and psoriatic arthritis. It is also used off label"/>
 <result pre="JAK3 inhibitor, is indicated in rheumatoid arthritis, ulcerative colitis, and" exact="psoriatic arthritis." post="It is also used off label for vitiligo and"/>
 <result pre="and psoriatic arthritis. It is also used off label for" exact="vitiligo" post="and alopecia areata. Tofacitinib treats inflammatory diseases by interfering"/>
 <result pre="arthritis. It is also used off label for vitiligo and" exact="alopecia" post="areata. Tofacitinib treats inflammatory diseases by interfering with the"/>
 <result pre="HTLV-1, a retrovirus, has been linked to diseases such as" exact="adult" post="T-cell lymphoma/leukemia (ATLL), HTLV-1-associated myelopathy (HAM), and uveitis. Ex"/>
 <result pre="linked to diseases such as adult T-cell lymphoma/leukemia (ATLL), HTLV-1-associated" exact="myelopathy" post="(HAM), and uveitis. Ex vivo and animal studies revealed"/>
 <result pre="However, it may be used as a second-line drug for" exact="psoriasis" post="and palmoplantar pustulosis115 based on the ability to slow"/>
 <result pre="is the major and common adverse effect of hydroxyurea. Human" exact="immunodeficiency" post="virus Hydroxyurea demonstrated promising results in reducing HIV RNA"/>
 <result pre="immunodeficiency virus Hydroxyurea demonstrated promising results in reducing HIV RNA" exact="viral" post="loads in five placebo-controlled clinical trials. Among all the"/>
 <result pre="DNA synthesis and in turn slows down the production of" exact="viral" post="DNA. Second, hydroxyurea enhances NRTI phosphorylation and reduces resistance"/>
 <result pre="partially explain the benefits of adding hydroxyurea to NRTI for" exact="viral" post="control. Finally, cytotoxic effect of hydroxyurea makes cellular division"/>
 <result pre="because HIV could only replicate in dividing CD4+ T cells.64" exact="Hepatitis" post="C virus, hepatitis B virus, herpes simplex virus (HSV),"/>
 <result pre="only replicate in dividing CD4+ T cells.64 Hepatitis C virus," exact="hepatitis" post="B virus, herpes simplex virus (HSV), parvovirus B19 (B19V)"/>
 <result pre="dividing CD4+ T cells.64 Hepatitis C virus, hepatitis B virus," exact="herpes" post="simplex virus (HSV), parvovirus B19 (B19V) Although the mode"/>
 <result pre="of hydroxyurea for HCV, HBV, HSV, and B19V is unknown," exact="viral" post="replications were inhibited by hydroxyurea in in vitro studies.70,74â€&quot;76"/>
 <result pre="trials showed significant reduction of HCV RNA levels and HBV" exact="viral" post="loads in chronic HCV and HBV carriers, respectively.71,72 However,"/>
 <result pre="reduction of HCV RNA levels and HBV viral loads in" exact="chronic" post="HCV and HBV carriers, respectively.71,72 However, there is a"/>
 <result pre="there is a case report of an elderly patient with" exact="essential thrombocythemia" post="experiencing reactivation of HBV during treatment with hydroxyurea.73 A"/>
 <result pre="is a case report of an elderly patient with essential" exact="thrombocythemia" post="experiencing reactivation of HBV during treatment with hydroxyurea.73 A"/>
 <result pre="during treatment with hydroxyurea.73 A retrospective review of children with" exact="sickle cell anemia" post="demonstrated decreased requirement of blood transfusion and attenuation of"/>
 <result pre="with hydroxyurea.73 A retrospective review of children with sickle cell" exact="anemia" post="demonstrated decreased requirement of blood transfusion and attenuation of"/>
 <result pre="Minocycline Minocycline, a second-generation of tetracyclines, is frequently used for" exact="bacterial infections," post="acne, and rheumatoid arthritis. The small size and lipophilic"/>
 <result pre="of tetracyclines, is frequently used for bacterial infections, acne, and" exact="rheumatoid arthritis." post="The small size and lipophilic nature facilitate its penetration"/>
 <result pre="and anti-inflammation effects116,117 brought interest in the treatment of virus-induced" exact="encephalitis" post="such as HIV, Japanese encephalitis virus (JEV), and reovirus."/>
 <result pre="interest in the treatment of virus-induced encephalitis such as HIV," exact="Japanese encephalitis" post="virus (JEV), and reovirus. The antiviral property is not"/>
 <result pre="in the treatment of virus-induced encephalitis such as HIV, Japanese" exact="encephalitis" post="virus (JEV), and reovirus. The antiviral property is not"/>
 <result pre="but seems to be diverse, including neuroprotective, antiapoptotic, interference of" exact="viral" post="protein expression, and anti-inflammatory effects. Human immunodeficiency virus In"/>
 <result pre="antiapoptotic, interference of viral protein expression, and anti-inflammatory effects. Human" exact="immunodeficiency" post="virus In microglial cell culture, minocycline reduced viral replication"/>
 <result pre="effects. Human immunodeficiency virus In microglial cell culture, minocycline reduced" exact="viral" post="replication by 71â€&quot;96%.78In vivo, macaque monkeys treated with minocycline"/>
 <result pre="destruction of axons and less replication of viruses in the" exact="central nervous system." post="The experiment suggested that the antiviral effect of minocycline"/>
 <result pre="minocycline was through reducing the activation of monocytes and hence," exact="viral" post="replication was blocked.79 Nevertheless, two double-blind, randomized, placebo-controlled human"/>
 <result pre="there was no difference in cognitive function compared with placebo.80,81" exact="Japanese encephalitis" post="virus Minocycline showed high efficacy in animal models and"/>
 <result pre="was no difference in cognitive function compared with placebo.80,81 Japanese" exact="encephalitis" post="virus Minocycline showed high efficacy in animal models and"/>
 <result pre="better outcomes, especially those who survived the first hospital day.85" exact="Dengue" post="virus, respiratory syncytial virus, enterovirus 71, influenza virus, West"/>
 <result pre="especially those who survived the first hospital day.85 Dengue virus," exact="respiratory" post="syncytial virus, enterovirus 71, influenza virus, West Nile virus,"/>
 <result pre="syncytial virus, enterovirus 71, influenza virus, West Nile virus, reovirus," exact="rabies" post="Minocycline showed antiviral activity in a broad spectrum of"/>
 <result pre="spectrum of other viruses, but most of the evidence was" exact="limited" post="to animal or in vitro studies.86â€&quot;91 On the contrary,"/>
 <result pre="in vitro studies.86â€&quot;91 On the contrary, an animal experiment with" exact="rabies" post="virus infection treated by minocycline caused the exacerbation of"/>
 <result pre="vitro studies.86â€&quot;91 On the contrary, an animal experiment with rabies" exact="virus infection" post="treated by minocycline caused the exacerbation of encephalomyelitis and"/>
 <result pre="studies.86â€&quot;91 On the contrary, an animal experiment with rabies virus" exact="infection" post="treated by minocycline caused the exacerbation of encephalomyelitis and"/>
 <result pre="rabies virus infection treated by minocycline caused the exacerbation of" exact="encephalomyelitis" post="and higher mortality rate.92 Chloroquine and hydroxychloroquine Severe acute"/>
 <result pre="exacerbation of encephalomyelitis and higher mortality rate.92 Chloroquine and hydroxychloroquine" exact="Severe" post="acute respiratory syndrome coronavirus (SARS-CoV) CQ and HCQ are"/>
 <result pre="of encephalomyelitis and higher mortality rate.92 Chloroquine and hydroxychloroquine Severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) CQ and HCQ are reported"/>
 <result pre="encephalomyelitis and higher mortality rate.92 Chloroquine and hydroxychloroquine Severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) CQ and HCQ are reported to"/>
 <result pre="and higher mortality rate.92 Chloroquine and hydroxychloroquine Severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) CQ and HCQ are reported to have"/>
 <result pre="SARS-CoV.30 Interestingly, the inhibitory effect was noted before and after" exact="viral" post="entry, which means CQ may offer benefit for both"/>
 <result pre="CQ may offer benefit for both prophylaxis and treatment.31,32 Human" exact="immunodeficiency" post="virus (HIV), dengue virus, chikungunya virus, influenza A virus,"/>
 <result pre="both prophylaxis and treatment.31,32 Human immunodeficiency virus (HIV), dengue virus," exact="chikungunya" post="virus, influenza A virus, hepatitis C virus (HCV) Some"/>
 <result pre="immunodeficiency virus (HIV), dengue virus, chikungunya virus, influenza A virus," exact="hepatitis C" post="virus (HCV) Some in vitro studies and clinical trials"/>
 <result pre="in the literature. Therefore, the utilization of CQ in these" exact="viral" post="diseases still needs further investigation. Zika virus The major"/>
 <result pre="needs further investigation. Zika virus The major concern of Zika" exact="virus infection" post="is that it can transmit from placenta to fetus"/>
 <result pre="further investigation. Zika virus The major concern of Zika virus" exact="infection" post="is that it can transmit from placenta to fetus"/>
 <result pre="that it can transmit from placenta to fetus and cause" exact="microcephaly" post="or congenital defects. CQ prevented Zika virus internalization in"/>
 <result pre="can transmit from placenta to fetus and cause microcephaly or" exact="congenital" post="defects. CQ prevented Zika virus internalization in cell cultures"/>
 <result pre="the expression of IFN genes and reduce the production of" exact="type I" post="IFNs. This phenomenon was noted in vitro118 and in"/>
 <result pre="phenomenon was noted in vitro118 and in human studies of" exact="autoimmune" post="diseases.119 Since IFNs are crucial in innate immunity to"/>
 <result pre="diseases.119 Since IFNs are crucial in innate immunity to defend" exact="viral" post="infections, the usage of HCQ may raise concerns about"/>
 <result pre="of HCQ may raise concerns about the counter effects in" exact="viral" post="control. Nevertheless, opposite results were also presented: HCQ activated"/>
 <result pre="signaling pathways in cell studies of dengue virus.120 Furthermore, blocking" exact="type I" post="IFN receptors attenuated the efficacy of HCQ in the"/>
 <result pre="On the other hand, a case-control study revealed patients with" exact="lupus erythematosus" post="were 16 times less likely to develop serious infections"/>
 <result pre="lupus erythematosus were 16 times less likely to develop serious" exact="infections" post="if taking antimalarials.121 Another retrospective study showed significantly lower"/>
 <result pre="serious infections if taking antimalarials.121 Another retrospective study showed significantly" exact="lower" post="infection rate in patients with lupus nephritis and exposure"/>
 <result pre="infections if taking antimalarials.121 Another retrospective study showed significantly lower" exact="infection" post="rate in patients with lupus nephritis and exposure to"/>
 <result pre="retrospective study showed significantly lower infection rate in patients with" exact="lupus" post="nephritis and exposure to antimalarials.122 HCQ is generally thought"/>
 <result pre="study showed significantly lower infection rate in patients with lupus" exact="nephritis" post="and exposure to antimalarials.122 HCQ is generally thought of"/>
 <result pre="HCQ is generally thought of as having protective effect for" exact="viral" post="infection,123 but their relationship with IFNs still needs further"/>
 <result pre="relationship with IFNs still needs further investigation. Cyclosporine A Human" exact="immunodeficiency" post="virus In vitro cyclophilin A interacts with the gag"/>
 <result pre="median exposure time of 11â€‰months on CsA (7.5â€‰mg/kg per day)," exact="stable" post="CD4 numbers were demonstrated, and none of the patients"/>
 <result pre="HIV RNA levels raised slightly (that was statistically significant) instead.57" exact="Hepatitis" post="C virus A controlled trial enrolled 120 chronic HCV"/>
 <result pre="significant) instead.57 Hepatitis C virus A controlled trial enrolled 120" exact="chronic" post="HCV carriers into two groups: IFN-Î± alone or a"/>
 <result pre="especially marked in patients with HCV genotype 1 and high" exact="viral" post="loads.60 NS5A and NS5B are two important non-structural proteins"/>
 <result pre="viruses belonging to this genus (dengue virus, West Nile virus," exact="yellow fever" post="virus and Zika virus). The efficacy of CsA is"/>
 <result pre="as one of the environmental factors triggering the recurrence of" exact="primary" post="biliary cirrhosis (PBC) after liver transplantation. Earlier and more"/>
 <result pre="of the environmental factors triggering the recurrence of primary biliary" exact="cirrhosis" post="(PBC) after liver transplantation. Earlier and more severe recurrence"/>
 <result pre="an in vitro study, it was suggested that CsA interrupted" exact="viral" post="replication through inhibiting viral protein synthesis, gag and envelope"/>
 <result pre="it was suggested that CsA interrupted viral replication through inhibiting" exact="viral" post="protein synthesis, gag and envelope assembly, and particle budding.63"/>
 <result pre="assembly, and particle budding.63 Mycophenolate mofetil and mycophenolic acid Human" exact="immunodeficiency" post="virus The combination of MMF and highly active antiretroviral"/>
 <result pre="MMF and highly active antiretroviral therapy improved the control of" exact="viral" post="replication and delayed viral-load rebound in a randomized pilot"/>
 <result pre="of MMF on influenza virus was through the inhibition of" exact="viral" post="messenger RNA and protein expression by inhibiting the cellular"/>
 <result pre="expression by inhibiting the cellular IMPDH. Besides, MMF markedly reduced" exact="viral" post="loads in lungs and all mice survived.94 Middle East"/>
 <result pre="viral loads in lungs and all mice survived.94 Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) MERS-CoV causes respiratory infection called MERS"/>
 <result pre="loads in lungs and all mice survived.94 Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) MERS-CoV causes respiratory infection called MERS or"/>
 <result pre="mice survived.94 Middle East respiratory syndrome coronavirus (MERS-CoV) MERS-CoV causes" exact="respiratory" post="infection called MERS or camel flu. Mortality rate is"/>
 <result pre="survived.94 Middle East respiratory syndrome coronavirus (MERS-CoV) MERS-CoV causes respiratory" exact="infection" post="called MERS or camel flu. Mortality rate is around"/>
 <result pre="and there is no specific treatment or vaccine for the" exact="disease" post="till now. MMF is one of the retrieved medications"/>
 <result pre="Human herpesvirus 8 (HHV-8) HHV-8 is the cause of Kaposiâ€™s" exact="sarcoma" post="(KS). Case reports showed encouraging experience of thalidomide in"/>
 <result pre="clinical trials investigating HIV-related KS revealed 35% and 40% of" exact="partial" post="responders. Serum titers of HHV-8 were decreased in all"/>
 <result pre="through immunosuppressive and anti-inflammatory effects with the possibility of higher" exact="infection" post="risk. However, many none-biologic DMARDs demonstrate antiviral activities instead."/>
 <result pre="useful in the choice of DMARDs for patients with concomitant" exact="viral" post="infections. Also, the combinational use of antiviral drugs and"/>
 <result pre="more effective and less resistant in the control of some" exact="viral" post="infections. Furthermore, in the face of novel viral infection,"/>
 <result pre="of some viral infections. Furthermore, in the face of novel" exact="viral infection," post="such as SARS-CoV-2, screening of existing chemicals, including DMARDs,"/>
 <result pre="Tsai and T. F. Tsai in Therapeutic Advances in Musculoskeletal" exact="Disease" post="Conflict of interest statement: Dr Tsen-Fang Tsai has conducted"/>
 <result pre="of antiviral and immunosuppressive drugs for the treatment of severe" exact="acute" post="exacerbation of chronic hepatitis B. J Gastroenterol2008; 43: 711â€&quot;719.18807133"/>
 <result pre="immunosuppressive drugs for the treatment of severe acute exacerbation of" exact="chronic hepatitis" post="B. J Gastroenterol2008; 43: 711â€&quot;719.18807133 2PotterCWPhairJPVodinelichL, et al.Antiviral, immunosuppressive"/>
 <result pre="drugs for the treatment of severe acute exacerbation of chronic" exact="hepatitis" post="B. J Gastroenterol2008; 43: 711â€&quot;719.18807133 2PotterCWPhairJPVodinelichL, et al.Antiviral, immunosuppressive"/>
 <result pre="analogs as a promising strategy for the treatment of emerging" exact="viral" post="diseases. Pharmacol Res Perspect2017; 5: e00293.28596841 5WangMCaoRZhangL, et al.Remdesivir"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studies. Biosci Trends2020; 14: 72â€&quot;73.32074550 7GautretPLagierJCParolaP, et"/>
 <result pre="et al.Hydroxychloroquine in patients with mainly mild to moderate coronavirus" exact="disease" post="2019: open label, randomised controlled trial. BMJ2020; 369: m1849.32409561"/>
 <result pre="with low-dose short-term glucocorticoid in the treatment of critical Coronvirus" exact="Disease" post="2019. Clin Transl Med. Epub ahead of print 4"/>
 <result pre="DOI: 10.1002/ctm2.35. 16RichardsonPGriffinITuckerC, et al.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory disease. Lancet2020; 395: e30â€&quot;e31.32032529 17MehtaPMcAuleyDFBrownM, et al.COVID-19: consider"/>
 <result pre="10.1002/ctm2.35. 16RichardsonPGriffinITuckerC, et al.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="disease. Lancet2020; 395: e30â€&quot;e31.32032529 17MehtaPMcAuleyDFBrownM, et al.COVID-19: consider cytokine"/>
 <result pre="et al.Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated" exact="interstitial lung disease." post="Rheumatol Int2016; 36: 125â€&quot;131.26223808 26GarcÃ­aFPlanaMArnedoM, et al.Effect of mycophenolate"/>
 <result pre="al.Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial" exact="lung disease." post="Rheumatol Int2016; 36: 125â€&quot;131.26223808 26GarcÃ­aFPlanaMArnedoM, et al.Effect of mycophenolate"/>
 <result pre="mycophenolate mofetil on immune response and plasma and lymphatic tissue" exact="viral" post="load during and after interruption of highly active antiretroviral"/>
 <result pre="after interruption of highly active antiretroviral therapy for patients with" exact="chronic" post="HIV infection: a randomized pilot study. J Acquir Immune"/>
 <result pre="and broad-spectrum in vitro antiviral activity against pandemic, seasonal and" exact="avian influenza" post="viruses affecting humans. J Gen Virol2016; 97: 1807â€&quot;1817.27259985 28HeYPeiRXuZ,"/>
 <result pre="et al.Reconstitution of the receptor-binding motif of the SARS coronavirus." exact="Protein" post="Eng Des Sel2015; 28: 567â€&quot;575.26487711 31KeyaertsEVijgenLMaesP, et al.In vitro"/>
 <result pre="Sel2015; 28: 567â€&quot;575.26487711 31KeyaertsEVijgenLMaesP, et al.In vitro inhibition of severe" exact="acute" post="respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun2004;"/>
 <result pre="28: 567â€&quot;575.26487711 31KeyaertsEVijgenLMaesP, et al.In vitro inhibition of severe acute" exact="respiratory" post="syndrome coronavirus by chloroquine. Biochem Biophys Res Commun2004; 323:"/>
 <result pre="567â€&quot;575.26487711 31KeyaertsEVijgenLMaesP, et al.In vitro inhibition of severe acute respiratory" exact="syndrome" post="coronavirus by chloroquine. Biochem Biophys Res Commun2004; 323: 264â€&quot;268.15351731"/>
 <result pre="32VincentMJBergeronEBenjannetS, et al.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virol J2005; 2: 69.16115318 33SavarinoAGenneroLChenHC, et al.Anti-HIV"/>
 <result pre="61: 1531â€&quot;1535.11377382 35SperberKLouieMKrausT, et al.Hydroxychloroquine treatment of patients with human" exact="immunodeficiency" post="virus type 1. Clin Ther1995; 17: 622â€&quot;636.8565026 36NeelyMKalyesubulaIBagendaD, et"/>
 <result pre="35SperberKLouieMKrausT, et al.Hydroxychloroquine treatment of patients with human immunodeficiency virus" exact="type 1." post="Clin Ther1995; 17: 622â€&quot;636.8565026 36NeelyMKalyesubulaIBagendaD, et al.Effect of chloroquine"/>
 <result pre="Ther1995; 17: 622â€&quot;636.8565026 36NeelyMKalyesubulaIBagendaD, et al.Effect of chloroquine on human" exact="immunodeficiency" post="virus (HIV) vertical transmission. Afr Health Sci2003; 3: 61â€&quot;67.12913796"/>
 <result pre="37MurraySMDownCMBoulwareDR, et al.Reduction of immune activation with chloroquine therapy during" exact="chronic" post="HIV infection. J Virol2010; 84: 12082â€&quot;12086.20844049 38PiconiSParisottoSRizzardiniG, et al.Hydroxychloroquine"/>
 <result pre="et al.Reduction of immune activation with chloroquine therapy during chronic" exact="HIV infection." post="J Virol2010; 84: 12082â€&quot;12086.20844049 38PiconiSParisottoSRizzardiniG, et al.Hydroxychloroquine drastically reduces"/>
 <result pre="3263â€&quot;3272.21576701 39PatonNIGoodallRLDunnDT, et al.Effects of hydroxychloroquine on immune activation and" exact="disease" post="progression among HIV-infected patients not receiving antiretroviral therapy: a"/>
 <result pre="therapy. HIV Med2015; 16: 48â€&quot;56.24889179 41FariasKJMachadoPRDa FonsecaBA.Chloroquine inhibits dengue virus" exact="type 2" post="replication in Vero cells but not in C6/36 cells."/>
 <result pre="282734.23431254 42FariasKJMachadoPRMunizJA, et al.Antiviral activity of chloroquine against dengue virus" exact="type 2" post="replication in Aotus monkeys. Viral Immunol2015; 28: 161â€&quot;169.25664975 43BorgesMCCastroLAFonsecaBA.Chloroquine"/>
 <result pre="chloroquine against dengue virus type 2 replication in Aotus monkeys." exact="Viral" post="Immunol2015; 28: 161â€&quot;169.25664975 43BorgesMCCastroLAFonsecaBA.Chloroquine use improves dengue-related symptoms. Mem"/>
 <result pre="challenges. Drug Discov Today2013; 18: 969â€&quot;983.23684571 46BrightonSW.Chloroquine phosphate treatment of" exact="chronic" post="chikungunya arthritis. An open pilot study. S Afr Med"/>
 <result pre="Drug Discov Today2013; 18: 969â€&quot;983.23684571 46BrightonSW.Chloroquine phosphate treatment of chronic" exact="chikungunya" post="arthritis. An open pilot study. S Afr Med J1984;"/>
 <result pre="S Afr Med J1984; 66: 217â€&quot;218.6087474 47De LamballerieXBoissonVReynierJC, et al.On" exact="chikungunya" post="acute infection and chloroquine treatment. Vector Borne Zoonotic Dis2008;"/>
 <result pre="Afr Med J1984; 66: 217â€&quot;218.6087474 47De LamballerieXBoissonVReynierJC, et al.On chikungunya" exact="acute" post="infection and chloroquine treatment. Vector Borne Zoonotic Dis2008; 8:"/>
 <result pre="Med J1984; 66: 217â€&quot;218.6087474 47De LamballerieXBoissonVReynierJC, et al.On chikungunya acute" exact="infection" post="and chloroquine treatment. Vector Borne Zoonotic Dis2008; 8: 837â€&quot;839.18620511"/>
 <result pre="49YanYZouZSunY, et al.Anti-malaria drug chloroquine is highly effective in treating" exact="avian influenza" post="A H5N1 virus infection in an animal model. Cell"/>
 <result pre="chloroquine is highly effective in treating avian influenza A H5N1" exact="virus infection" post="in an animal model. Cell Res2013; 23: 300â€&quot;302.23208422 50BorbaEFSaadCGPasotoSG,"/>
 <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal model. Cell Res2013; 23: 300â€&quot;302.23208422 50BorbaEFSaadCGPasotoSG,"/>
 <result pre="11: 951â€&quot;954.23109461 54LiCZhuXJiX, et al.Chloroquine, a FDA-approved drug, prevents zika" exact="virus infection" post="and its associated congenital microcephaly in mice. EBioMedicine2017; 24:"/>
 <result pre="951â€&quot;954.23109461 54LiCZhuXJiX, et al.Chloroquine, a FDA-approved drug, prevents zika virus" exact="infection" post="and its associated congenital microcephaly in mice. EBioMedicine2017; 24:"/>
 <result pre="a FDA-approved drug, prevents zika virus infection and its associated" exact="congenital" post="microcephaly in mice. EBioMedicine2017; 24: 189â€&quot;194.29033372 55ThaliMBukovskyAKondoE, et al.Functional"/>
 <result pre="FDA-approved drug, prevents zika virus infection and its associated congenital" exact="microcephaly" post="in mice. EBioMedicine2017; 24: 189â€&quot;194.29033372 55ThaliMBukovskyAKondoE, et al.Functional association"/>
 <result pre="prolylpeptidyl isomerase activity in the structure and function of the" exact="hepatitis C" post="virus replication complex. J Virol2009; 83: 6554â€&quot;6565.19386705 59WatashiKIshiiNHijikataM, et"/>
 <result pre="6554â€&quot;6565.19386705 59WatashiKIshiiNHijikataM, et al.Cyclophilin B is a functional regulator of" exact="hepatitis C" post="virus RNA polymerase. Mol Cell2005; 19: 111â€&quot;122.15989969 60InoueKSekiyamaKYamadaM, et"/>
 <result pre="al.Combined interferon alpha2b and cyclosporin A in the treatment of" exact="chronic hepatitis" post="C: controlled trial. J Gastroenterol2003; 38: 567â€&quot;572.12825133 61QingMYangFZhangB, et"/>
 <result pre="interferon alpha2b and cyclosporin A in the treatment of chronic" exact="hepatitis" post="C: controlled trial. J Gastroenterol2003; 38: 567â€&quot;572.12825133 61QingMYangFZhangB, et"/>
 <result pre="flavivirus replication through blocking the interaction between host cyclophilins and" exact="viral" post="NS5 protein. Antimicrob Agents Chemother2009; 53: 3226â€&quot;3235.19451286 62BarrowsNJCamposRKPowellST, et"/>
 <result pre="et al.A screen of FDA-approved drugs for inhibitors of zika" exact="virus infection." post="Cell Host Microbe2016; 20: 259â€&quot;270.27476412 63Montano-LozaAJWasilenkoSBintnerJ, et al.Cyclosporine A"/>
 <result pre="al.Cyclosporine A inhibits in vitro replication of betaretrovirus associated with" exact="primary" post="biliary cirrhosis. Liver Int2010; 30: 871â€&quot;877.20492501 64LoriFLisziewiczJ.Rationale for the"/>
 <result pre="871â€&quot;877.20492501 64LoriFLisziewiczJ.Rationale for the use of hydroxyurea as an anti-human" exact="immunodeficiency" post="virus drug. Clin Infect Dis2000; 30(Suppl. 2): S193â€&quot;S197.10860905 65LoriFMalykhAGFoliA,"/>
 <result pre="the cell with a drug targeting the virus controls human" exact="immunodeficiency" post="virus type 1 resistance. AIDS Res Hum Retroviruses1997; 13:"/>
 <result pre="with a drug targeting the virus controls human immunodeficiency virus" exact="type 1" post="resistance. AIDS Res Hum Retroviruses1997; 13: 1403â€&quot;1409.9359660 66RutschmannOTOpravilMItenA, et"/>
 <result pre="trial of didanosine plus stavudine, with and without hydroxyurea, for" exact="HIV infection." post="The Swiss HIV cohort study. AIDS1998; 12: F71â€&quot;F77.9631134 67LafeuilladeAHittingerGChadapaudS,"/>
 <result pre="Chemother2004; 53: 501â€&quot;505.14762056 70NozakiAMorimotoMKondoM, et al.Hydroxyurea as an inhibitor of" exact="hepatitis C" post="virus RNA replication. Arch Virol2010; 155: 601â€&quot;605.20204428 71NozakiANumataKMorimotoM, et"/>
 <result pre="in humans: a phase I trial of oral hydroxyurea in" exact="chronic hepatitis C" post="patients. Antivir Ther2010; 15: 1179â€&quot;1183.21149925 72KashaniHHVossoughiAAdibiP, et al.Amazing results"/>
 <result pre="humans: a phase I trial of oral hydroxyurea in chronic" exact="hepatitis C" post="patients. Antivir Ther2010; 15: 1179â€&quot;1183.21149925 72KashaniHHVossoughiAAdibiP, et al.Amazing results"/>
 <result pre="15: 1179â€&quot;1183.21149925 72KashaniHHVossoughiAAdibiP, et al.Amazing results with hydroxyurea therapy in" exact="chronic hepatitis" post="B: a preliminary report. Hepat Mon2010; 10: 215â€&quot;217.22308141 73WatanabeNYasudaHAotaY,"/>
 <result pre="1179â€&quot;1183.21149925 72KashaniHHVossoughiAAdibiP, et al.Amazing results with hydroxyurea therapy in chronic" exact="hepatitis" post="B: a preliminary report. Hepat Mon2010; 10: 215â€&quot;217.22308141 73WatanabeNYasudaHAotaY,"/>
 <result pre="preliminary report. Hepat Mon2010; 10: 215â€&quot;217.22308141 73WatanabeNYasudaHAotaY, et al.Reactivation of" exact="hepatitis" post="B virus during treatment with hydroxyurea in an elderly"/>
 <result pre="virus during treatment with hydroxyurea in an elderly patient with" exact="essential thrombocythemia." post="Geriatr Gerontol Int2015; 15: 812â€&quot;813.26031797 74RosenkranzHSBeckerY.Reversible inhibition of herpes"/>
 <result pre="essential thrombocythemia. Geriatr Gerontol Int2015; 15: 812â€&quot;813.26031797 74RosenkranzHSBeckerY.Reversible inhibition of" exact="herpes" post="simplex virus replication by hydroxyurea. Antimicrob Agents Chemother1973; 3:"/>
 <result pre="325â€&quot;331.4364174 75SergerieYBoivinG.Hydroxyurea enhances the activity of acyclovir and cidofovir against" exact="herpes" post="simplex virus type 1 resistant strains harboring mutations in"/>
 <result pre="the activity of acyclovir and cidofovir against herpes simplex virus" exact="type 1" post="resistant strains harboring mutations in the thymidine kinase and/or"/>
 <result pre="Biochem Pharmacol2017; 136: 32â€&quot;39.28377277 77HankinsJSPenkertRRLavoieP, et al.Original research: parvovirus B19" exact="infection" post="in children with sickle cell disease in the hydroxyurea"/>
 <result pre="77HankinsJSPenkertRRLavoieP, et al.Original research: parvovirus B19 infection in children with" exact="sickle cell disease" post="in the hydroxyurea era. Exp Biol Med (Maywood)2016; 241:"/>
 <result pre="al.Original research: parvovirus B19 infection in children with sickle cell" exact="disease" post="in the hydroxyurea era. Exp Biol Med (Maywood)2016; 241:"/>
 <result pre="78SiQCosenzaMKimMO, et al.A novel action of minocycline inhibition of human" exact="immunodeficiency" post="virus type 1 infection in microglia. J Neurovirol2004; 10:"/>
 <result pre="al.A novel action of minocycline inhibition of human immunodeficiency virus" exact="type 1" post="infection in microglia. J Neurovirol2004; 10: 284â€&quot;292.15385251 79ZinkMCUhrlaubJDeWittJ, et"/>
 <result pre="action of minocycline inhibition of human immunodeficiency virus type 1" exact="infection" post="in microglia. J Neurovirol2004; 10: 284â€&quot;292.15385251 79ZinkMCUhrlaubJDeWittJ, et al.Neuroprotective"/>
 <result pre="microglia. J Neurovirol2004; 10: 284â€&quot;292.15385251 79ZinkMCUhrlaubJDeWittJ, et al.Neuroprotective and anti-human" exact="immunodeficiency" post="virus activity of minocycline. JAMA2005; 293: 2003â€&quot;2011.15855434 80SacktorNMiyaharaSDengL, et"/>
 <result pre="et al.Randomized trial of minocycline in the treatment of HIV-associated" exact="cognitive impairment." post="Neurology2013; 80: 196â€&quot;202.23269596 82MishraMKBasuA.Minocycline neuroprotects, reduces microglial activation, inhibits"/>
 <result pre="82MishraMKBasuA.Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction, and" exact="viral" post="replication following Japanese encephalitis. J Neurochem2008; 105: 1582â€&quot;1595.18208541 83DuttaKKumawatKLNazmiA,"/>
 <result pre="microglial activation, inhibits caspase 3 induction, and viral replication following" exact="Japanese encephalitis." post="J Neurochem2008; 105: 1582â€&quot;1595.18208541 83DuttaKKumawatKLNazmiA, et al.Minocycline differentially modulates"/>
 <result pre="encephalitis. J Neurochem2008; 105: 1582â€&quot;1595.18208541 83DuttaKKumawatKLNazmiA, et al.Minocycline differentially modulates" exact="viral infection" post="and persistence in an experimental model of Japanese encephalitis."/>
 <result pre="J Neurochem2008; 105: 1582â€&quot;1595.18208541 83DuttaKKumawatKLNazmiA, et al.Minocycline differentially modulates viral" exact="infection" post="and persistence in an experimental model of Japanese encephalitis."/>
 <result pre="modulates viral infection and persistence in an experimental model of" exact="Japanese encephalitis." post="J Neuroimmune Pharmacol2010; 5: 553â€&quot;565.20635157 84SinghAMehtaAKushwahaKP, et al.Minocycline trial"/>
 <result pre="Res2016; 3: 371â€&quot;377. 85KumarRBasuASinhaS, et al.Role of oral minocycline in" exact="acute" post="encephalitis syndrome in India: a randomized controlled trial. BMC"/>
 <result pre="3: 371â€&quot;377. 85KumarRBasuASinhaS, et al.Role of oral minocycline in acute" exact="encephalitis" post="syndrome in India: a randomized controlled trial. BMC Infect"/>
 <result pre="371â€&quot;377. 85KumarRBasuASinhaS, et al.Role of oral minocycline in acute encephalitis" exact="syndrome" post="in India: a randomized controlled trial. BMC Infect Dis2016;"/>
 <result pre="16: 67.26847071 86LeelaSLSrisawatCSreekanthGP, et al.Drug repurposing of minocycline against dengue" exact="virus infection." post="Biochem Biophys Res Commun2016; 478: 410â€&quot;416.27396621 87BawageSSTiwariPMPillaiS, et al.Antibiotic"/>
 <result pre="Biophys Res Commun2016; 478: 410â€&quot;416.27396621 87BawageSSTiwariPMPillaiS, et al.Antibiotic minocycline prevents" exact="respiratory" post="syncytial virus infection. Viruses2019; 11: 739. 88LiaoYTWangSMChenSH.Anti-inflammatory and antiviral"/>
 <result pre="Commun2016; 478: 410â€&quot;416.27396621 87BawageSSTiwariPMPillaiS, et al.Antibiotic minocycline prevents respiratory syncytial" exact="virus infection." post="Viruses2019; 11: 739. 88LiaoYTWangSMChenSH.Anti-inflammatory and antiviral effects of minocycline"/>
 <result pre="avian-origin influenza A (H7N9) virus: specific host response and responses" exact="intermediate" post="between avian (H5N1 and H7N7) and human (H3N2) viruses"/>
 <result pre="al.Minocycline inhibits West Nile virus replication and apoptosis in human" exact="neuronal" post="cells. J Antimicrob Chemother2007; 60: 981â€&quot;986.17872917 91Richardson-BurnsSMTylerKL.Minocycline delays disease"/>
 <result pre="human neuronal cells. J Antimicrob Chemother2007; 60: 981â€&quot;986.17872917 91Richardson-BurnsSMTylerKL.Minocycline delays" exact="disease" post="onset and mortality in reovirus encephalitis. Exp Neurol2005; 192:"/>
 <result pre="Neurol2005; 192: 331â€&quot;339.15755550 92JacksonACScottCAOwenJ, et al.Therapy with minocycline aggravates experimental" exact="rabies" post="in mice. J Virol2007; 81: 6248â€&quot;6253.17409147 93ChapuisAGPaolo RizzardiGDâ€™AgostinoC, et"/>
 <result pre="6248â€&quot;6253.17409147 93ChapuisAGPaolo RizzardiGDâ€™AgostinoC, et al.Effects of mycophenolic acid on human" exact="immunodeficiency" post="virus infection in vitro and in vivo. Nat Med2000;"/>
 <result pre="93ChapuisAGPaolo RizzardiGDâ€™AgostinoC, et al.Effects of mycophenolic acid on human immunodeficiency" exact="virus infection" post="in vitro and in vivo. Nat Med2000; 6: 762â€&quot;768.10888924"/>
 <result pre="RizzardiGDâ€™AgostinoC, et al.Effects of mycophenolic acid on human immunodeficiency virus" exact="infection" post="in vitro and in vivo. Nat Med2000; 6: 762â€&quot;768.10888924"/>
 <result pre="mofetil, an alternative antiviral and immunomodulator for the highly pathogenic" exact="avian influenza" post="H5N1 virus infection. Biochem Biophys Res Commun2017; 494: 298â€&quot;304.29017920"/>
 <result pre="antiviral and immunomodulator for the highly pathogenic avian influenza H5N1" exact="virus infection." post="Biochem Biophys Res Commun2017; 494: 298â€&quot;304.29017920 95ChanJFChanKHKaoRY, et al.Broad-spectrum"/>
 <result pre="298â€&quot;304.29017920 95ChanJFChanKHKaoRY, et al.Broad-spectrum antivirals for the emerging Middle East" exact="respiratory" post="syndrome coronavirus. J Infect2013; 67: 606â€&quot;616.24096239 96ChanJFYaoYYeungML, et al.Treatment"/>
 <result pre="95ChanJFChanKHKaoRY, et al.Broad-spectrum antivirals for the emerging Middle East respiratory" exact="syndrome" post="coronavirus. J Infect2013; 67: 606â€&quot;616.24096239 96ChanJFYaoYYeungML, et al.Treatment with"/>
 <result pre="et al.Treatment with lopinavir/ritonavir or interferon-Î²1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmoset. J"/>
 <result pre="marmoset. J Infect Dis2015; 212: 1904â€&quot;1913.26198719 97KnightDAHejmanowskiAQDierksheideJE, et al.Inhibition of" exact="herpes" post="simplex virus type 1 by the experimental immunosuppressive agent"/>
 <result pre="Dis2015; 212: 1904â€&quot;1913.26198719 97KnightDAHejmanowskiAQDierksheideJE, et al.Inhibition of herpes simplex virus" exact="type 1" post="by the experimental immunosuppressive agent leflunomide. Transplantation2001; 71: 170â€&quot;174.11211189"/>
 <result pre="leflunomide. Transplantation2001; 71: 170â€&quot;174.11211189 98Henao-MartÃ­nezAFWeinbergAWaldmanWJ, et al.Successful treatment of acyclovir-resistant" exact="herpes" post="simplex virus type 2 proctitis with leflunomide in an"/>
 <result pre="170â€&quot;174.11211189 98Henao-MartÃ­nezAFWeinbergAWaldmanWJ, et al.Successful treatment of acyclovir-resistant herpes simplex virus" exact="type 2" post="proctitis with leflunomide in an HIV-infected man. J Clin"/>
 <result pre="et al.Successful treatment of acyclovir-resistant herpes simplex virus type 2" exact="proctitis" post="with leflunomide in an HIV-infected man. J Clin Virol2012;"/>
 <result pre="Virol2012; 54: 276â€&quot;278.22465339 99RogerMRAnsteadGM.Leflunomide in the treatment of a pseudotumoral" exact="genital herpes" post="simplex virus infection in an HIV patient. Case Rep"/>
 <result pre="54: 276â€&quot;278.22465339 99RogerMRAnsteadGM.Leflunomide in the treatment of a pseudotumoral genital" exact="herpes" post="simplex virus infection in an HIV patient. Case Rep"/>
 <result pre="99RogerMRAnsteadGM.Leflunomide in the treatment of a pseudotumoral genital herpes simplex" exact="virus infection" post="in an HIV patient. Case Rep Infect Dis2017; 2017:"/>
 <result pre="in the treatment of a pseudotumoral genital herpes simplex virus" exact="infection" post="in an HIV patient. Case Rep Infect Dis2017; 2017:"/>
 <result pre="immune modulating drug that may have a role in controlling" exact="secondary" post="infections with review of its mechanisms of action. J"/>
 <result pre="modulating drug that may have a role in controlling secondary" exact="infections" post="with review of its mechanisms of action. J Drugs"/>
 <result pre="104NguyenLMcClellanRBChaudhuriA, et al.Conversion from tacrolimus/mycophenolic acid to tacrolimus/leflunomide to treat" exact="cutaneous" post="warts in a series of four pediatric renal allograft"/>
 <result pre="et al.Conversion from tacrolimus/mycophenolic acid to tacrolimus/leflunomide to treat cutaneous" exact="warts" post="in a series of four pediatric renal allograft recipients."/>
 <result pre="et al.Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus" exact="disease" post="after lung transplantation: case report and review of the"/>
 <result pre="recipients with untreated BK nephropathy. Transplantation2010; 90: 891â€&quot;897. 109DunnMCKnightDAWaldmanWJ.Inhibition of" exact="respiratory" post="syncytial virus in vitro and in vivo by the"/>
 <result pre="117: 1938â€&quot;1946.21106989 111FifeKHowardMRGracieF, et al.Activity of thalidomide in AIDS-related Kaposiâ€™s" exact="sarcoma" post="and correlation with HHV8 titre. Int J STD AIDS1998;"/>
 <result pre="113JohnGTManivannanJChandyS, et al.A prospective evaluation of leflunomide therapy for cytomegalovirus" exact="disease" post="in renal transplant recipients. Transplant Proc2005; 37: 4303â€&quot;4305.16387103 114ElliottNEClevelandSMGrannV,"/>
 <result pre="al.FERM domain mutations induce gain of function in JAK3 in" exact="adult" post="T-cell leukemia/lymphoma. Blood2011; 118: 3911â€&quot;3921.21821710 115HattelTSondergaardJ.Pustulosis palmaris et plantaris"/>
 <result pre="hydroxyurea. Acta Derm Venereol1974; 54: 152â€&quot;154.4133022 116PopovicNSchubartAGoetzBD, et al.Inhibition of" exact="autoimmune" post="encephalomyelitis by a tetracycline. Ann Neurol2002; 51: 215â€&quot;223.11835378 117SongYWeiEQZhangWP,"/>
 <result pre="Acta Derm Venereol1974; 54: 152â€&quot;154.4133022 116PopovicNSchubartAGoetzBD, et al.Inhibition of autoimmune" exact="encephalomyelitis" post="by a tetracycline. Ann Neurol2002; 51: 215â€&quot;223.11835378 117SongYWeiEQZhangWP, et"/>
 <result pre="Neuroreport2004; 15: 2181â€&quot;2184.15371729 118SacreKCriswellLAMcCuneJM.Hydroxychloroquine is associated with impaired interferon-alpha and" exact="tumor" post="necrosis factor-alpha production by plasmacytoid dendritic cells in systemic"/>
 <result pre="and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in" exact="systemic" post="lupus erythematosus. Arthritis Res Ther2012; 14: R155.22734582 119BodewesILAGottenbergJEvan Helden-MeeuwsenCG,"/>
 <result pre="tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic" exact="lupus erythematosus." post="Arthritis Res Ther2012; 14: R155.22734582 119BodewesILAGottenbergJEvan Helden-MeeuwsenCG, et al.Hydroxychloroquine"/>
 <result pre="factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus." exact="Arthritis" post="Res Ther2012; 14: R155.22734582 119BodewesILAGottenbergJEvan Helden-MeeuwsenCG, et al.Hydroxychloroquine treatment"/>
 <result pre="Res Ther2012; 14: R155.22734582 119BodewesILAGottenbergJEvan Helden-MeeuwsenCG, et al.Hydroxychloroquine treatment downregulates" exact="systemic" post="interferon activation in primary SjÃ¶grenâ€™s syndrome in the JOQUER"/>
 <result pre="119BodewesILAGottenbergJEvan Helden-MeeuwsenCG, et al.Hydroxychloroquine treatment downregulates systemic interferon activation in" exact="primary" post="SjÃ¶grenâ€™s syndrome in the JOQUER randomized trial. Rheumatology (Oxford)2020;"/>
 <result pre="et al.Hydroxychloroquine treatment downregulates systemic interferon activation in primary SjÃ¶grenâ€™s" exact="syndrome" post="in the JOQUER randomized trial. Rheumatology (Oxford)2020; 59: 107â€&quot;111.31237947"/>
 <result pre="Interferon Cytokine Res2015; 35: 143â€&quot;156.25321315 121Ruiz-IrastorzaGOlivaresNRuiz-ArruzaI, et al.Predictors of major" exact="infections" post="in systemic lupus erythematosus. Arthritis Res Ther2009; 11: R109.19604357"/>
 <result pre="Res2015; 35: 143â€&quot;156.25321315 121Ruiz-IrastorzaGOlivaresNRuiz-ArruzaI, et al.Predictors of major infections in" exact="systemic" post="lupus erythematosus. Arthritis Res Ther2009; 11: R109.19604357 122SisÃ³ARamos-CasalsMBovÃ©A, et"/>
 <result pre="35: 143â€&quot;156.25321315 121Ruiz-IrastorzaGOlivaresNRuiz-ArruzaI, et al.Predictors of major infections in systemic" exact="lupus erythematosus." post="Arthritis Res Ther2009; 11: R109.19604357 122SisÃ³ARamos-CasalsMBovÃ©A, et al.Previous antimalarial"/>
 <result pre="121Ruiz-IrastorzaGOlivaresNRuiz-ArruzaI, et al.Predictors of major infections in systemic lupus erythematosus." exact="Arthritis" post="Res Ther2009; 11: R109.19604357 122SisÃ³ARamos-CasalsMBovÃ©A, et al.Previous antimalarial therapy"/>
 <result pre="R109.19604357 122SisÃ³ARamos-CasalsMBovÃ©A, et al.Previous antimalarial therapy in patients diagnosed with" exact="lupus" post="nephritis: influence on outcomes and survival. Lupus2008; 17: 281â€&quot;288.18413408"/>
 <result pre="on outcomes and survival. Lupus2008; 17: 281â€&quot;288.18413408 123DanzaARuiz-IrastorzaG.Infection risk in" exact="systemic" post="lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus2013;"/>
 <result pre="outcomes and survival. Lupus2008; 17: 281â€&quot;288.18413408 123DanzaARuiz-IrastorzaG.Infection risk in systemic" exact="lupus erythematosus" post="patients: susceptibility factors and preventive strategies. Lupus2013; 22: 1286â€&quot;1294.24098001"/>
</results>
